CASI Pharmaceuticals Inc (Nasdaq: CASI), a biopharmaceutical company, announced on Friday that it has named George Chi as its new chief financial officer.
Chi most recently served as vice president of Finance at Flavors Holdings Inc. He led the global accounting function, including financial reporting, planning, treasury, investor relations, and tax and auditing with management responsibility for global sales in 90 countries. Prior to joining Flavor Holdings, he was Chief Financial Officer at BPL Plasma. Previously, Chi served as finance director at Unilever.
Dr Wei-Wu He, executive chairman of CASI Pharmaceuticals, said, 'I'm very pleased to announce George's appointment and welcome him to CASI. George joins us at an opportune time as our company prepares for the marketing and sales of our first oncology product in China. He will be integral to help transition the Company's financial operations to commercial stage as we launch EVOMELA and other additional products from our pipeline.'
The Nemours Children's Health System names new chair
Biopharma Veterans Kevin Young and Una Ryan Join Cortexyme Board of Directors
BioArctic reports approval by US FDA of Investigational New Drug Application for ABBV-0805
Seres Therapeutics Reports Corporate Changes to Focus on Advancing Clinical Assets
Hansa Biopharma names Donato Spota as new CFO
ESSA Pharma Inc incurs net loss of USD2.7m for Q1 fiscal 2018
Biogennix Names Baizer as Chief Financial Officer
Coro Health names new vice president of Business Development
KEPRO names new general counsel & chief compliance officer
Decibel Therapeutics Names Chief Medical Officer and Chief Operating Officer
VentureMed Group names new president and chief executive officer